Oh WK - Search Results

1

The evolving landscape of immunotherapy in advanced prostate cancer.

Patel VG, Oh WK. Patel VG, et al. Among authors: oh wk. Immunotherapy. 2019 Jul;11(10):903-912. doi: 10.2217/imt-2019-0019. Epub 2019 Jun 4. Immunotherapy. 2019. PMID: 31161846

2

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK. Tsao CK, et al. Among authors: oh wk. Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Curr Opin Urol. 2012. PMID: 22472508 Review.

3

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.

Galsky MD, Small AC, Tsao CK, Oh WK. Galsky MD, et al. Among authors: oh wk. CA Cancer J Clin. 2012 Sep-Oct;62(5):299-308. doi: 10.3322/caac.21141. Epub 2012 Apr 24. CA Cancer J Clin. 2012. PMID: 22535487 Free article. Review.

4

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Tsao CK, et al. Among authors: oh wk. BJU Int. 2012 Dec;110(11):1580-8. doi: 10.1111/j.1464-410X.2012.11445.x. Epub 2012 Sep 18. BJU Int. 2012. PMID: 22985411 Review.

5

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. Tsao CK, et al. Among authors: oh wk. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):835-46. doi: 10.1517/17425255.2013.789019. Epub 2013 Apr 12. Expert Opin Drug Metab Toxicol. 2013. PMID: 23581700 Review.

6

New paradigms in microtubule-mediated endocrine signaling in prostate cancer.

Mistry SJ, Oh WK. Mistry SJ, et al. Among authors: oh wk. Mol Cancer Ther. 2013 May;12(5):555-66. doi: 10.1158/1535-7163.MCT-12-0871. Epub 2013 May 1. Mol Cancer Ther. 2013. PMID: 23635655 Review.

7

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.

Tsao CK, Galsky MD, Oh WK. Tsao CK, et al. Among authors: oh wk. Eur Urol. 2014 Aug;66(2):184-5. doi: 10.1016/j.eururo.2013.12.061. Epub 2014 Jan 7. Eur Urol. 2014. PMID: 24433812

8

Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.

Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. Morgan CJ, et al. Among authors: oh wk. Crit Rev Oncol Hematol. 2014 Jun;90(3):253-61. doi: 10.1016/j.critrevonc.2013.12.001. Epub 2014 Feb 2. Crit Rev Oncol Hematol. 2014. PMID: 24500033 Review.

9

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.

Yu EY, Oh WK. Yu EY, et al. Among authors: oh wk. Asian J Androl. 2014 May-Jun;16(3):331-3. doi: 10.4103/1008-682X.127813. Asian J Androl. 2014. PMID: 24759585 Free PMC article. No abstract available.

10

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. Sonpavde G, et al. Among authors: oh wk. BJU Int. 2015 Jul;116(1):17-29. doi: 10.1111/bju.12867. Epub 2014 Oct 23. BJU Int. 2015. PMID: 25046451 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters